Cognitive & Neuro Regulation

Semax (ACTH(4–10) Analogue)

For Research Use Only. Not for Human or Veterinary Use.

Overview

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) based on the ACTH(4–10) fragment of adrenocorticotropic hormone, but engineered to keep the neuroactive core while dropping the parent hormone’s corticotropic activity. In research it is studied as a neurotrophic-factor inducer — raising BDNF and NGF — for cognitive and neuroprotection endpoints, and it is typically delivered intranasally. It is a research compound.

Chemical Profile

PropertyValue
CAS number80714-61-0
ClassSynthetic ACTH(4–10) analogue (heptapeptide)
Amino-acid sequenceH-Met-Glu-His-Phe-Pro-Gly-Pro-OH
One-letter codeMEHFPGP (7 aa)
Molecular formulaC₃₇H₅₁N₉O₁₀S
Molecular weight≈ 813.9 g/mol
Purity (HPLC)≥ 98%
AppearanceWhite to off-white lyophilized powder
Semax at a glance
Class
Synthetic ACTH(4–10) analogue
Research status
Preclinical and clinical (Eastern Europe)
Study routes
Intranasal (primary), IV, IM
Half-life
≈ 30 min (intranasal)
Key feature
Neurotrophic-factor (BDNF / NGF) inducer

Mechanism of Action

Semax keeps the CNS-active core of ACTH(4–10) but has no corticotropic (hormonal) activity. Its main studied action is inducing neurotrophic factors — chiefly BDNF and NGF — and the downstream TrkB/CREB signalling associated with neuroplasticity, with additional reported effects on dopamine and serotonin turnover.

ComponentDetail
Primary targetsBDNF/TrkB and NGF/TrkA signalling
Secondary targetsDopaminergic and serotonergic systems
Upstream mechanismPKC / PKA signalling cascades
CREBPhosphorylated CREB → neuroplasticity gene expression
Hormonal activityNone (unlike parent ACTH)
RegionStudied effect
CortexReduced ischemic damage (antioxidant, anti-apoptotic)
HippocampusEnhanced long-term potentiation (BDNF/TrkB)
StriatumDopaminergic protection
Cholinergic systemNGF-mediated support

Pharmacology

ParameterValue
Half-life (t½)≈ 30 min (intranasal); shorter IV
Bioavailability (intranasal)High — direct nose-to-brain delivery
Time to peak (Tmax)≈ 5–10 min (intranasal)
Protein binding≈ 30%
MetabolismProteolytic cleavage by exopeptidases
Route of administrationIntranasal, IV, IM
EliminationRenal (peptide fragments)

Research Evidence

Semax has preclinical and clinical (mainly Russian/Ukrainian) literature in stroke and cognition. Representative studies and their focus are named below; specific numerical outcomes are not restated here as claims.

Study typeResearch focusReference
Rodent ischemia modelsNeuroprotection and functional recoverySemax preclinical literature
Aged-rat cognitionAge-related cognitive declineSemax preclinical literature
Clinical stroke observationRecovery in ischemic strokeSemax clinical literature (Eastern Europe)

Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):

Reported direction / findingContextReference
Neuroprotection and functional recoveryrodent ischemia modelsSemax literature
Raises BDNF/NGF; cognitive effectsrodent cognitionSemax literature
Used in ischemic-stroke recovery researchclinical observation (Eastern Europe)Semax clinical literature

For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.

Dosing & Reconstitution Reference

Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.

ParameterReference value
Research dose range (literature)≈ 200–600 µg per dose (intranasal), in study protocols
Reconstitution solventBacteriostatic water (0.9% benzyl alcohol)
Storage (lyophilized)−20°C, protected from light
Storage (reconstituted)2–8°C, up to ~7 days
Do not useIf the solution is cloudy or contains particulates

Safety Profile

Published research observations, provided for reference only. This material is not for human or veterinary use.

CategoryPublished observations
TolerabilityWell tolerated in reported studies
HormonalNo corticotropic activity
Local (intranasal)Mild, transient nasal irritation possible
StatusFor research use only; not for human or veterinary application

Physicochemical Properties

PropertyValue
Physical stateWhite to off-white lyophilized powder
Solubility (water)Freely soluble
pH (reconstituted)5.0–7.0
Light sensitivityModerate
Stability (lyophilized)≥ 24 months at −20°C

Synthesis & Manufacturing

Semax is a 7-residue peptide made by Fmoc solid-phase synthesis. Its single methionine is oxidation-sensitive, so scavengers are used at cleavage, and the two prolines shape its overall handling.

StepDetail
StrategyFmoc solid-phase peptide synthesis
ResinWang resin (C-terminal acid)
CouplingHBTU / HOBt with DIPEA
Sensitive residueMet protected against oxidation; scavengers at cleavage
CleavageTFA / TIPS / H₂O with thiol scavengers
PurificationPreparative RP-HPLC (C18, TFA/ACN gradient)
  • Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
  • Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
  • Critical quality attributes: correct molecular weight and low deletion-peptide content. A single methionine is oxidation-sensitive; protect from air and light.

Analytical Methods

MethodParameterTypical result
RP-HPLC (C18, UV 214 nm)Purity≥ 98%
HPLC retentionC18, 10–40% B over 25 minSingle main peak
ESI-MS (positive mode)Identity / mass[M+H]⁺ ≈ 814 Da
MALDI-TOFMass confirmation[M+H]⁺ ≈ 814 Da
Amino-acid analysisCompositionConsistent with the stated sequence
LC-MS (extracted ion)Deletion-peptide impuritiesWithin specification
Karl FischerWater content< 6%
LAL assayEndotoxinWithin specification
Ion chromatographyResidual TFA< 500 ppm

Representative RP-HPLC purity method:

  • Column: C18, 5 µm, 250 × 4.6 mm
  • Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
  • Gradient: 10–40% B over 25 min · Flow rate: 1.0 mL/min · Detection: UV 214 nm
  • Confirmatory LC-MS: ESI positive mode ([M+H]⁺ ≈ 814 Da). A single methionine is oxidation-sensitive; protect from air and light.

Stability Data

Representative stability behaviour under common storage, handling and formulation conditions.

ConditionDurationResult
Lyophilized, −20°C, dark≥ 24 monthsNo significant degradation (purity > 97%)
Lyophilized, 2–8°C, dark≥ 12 monthsMinimal degradation (purity > 95%)
Lyophilized, 25°C (accelerated)3 months< 5% degradation
Reconstituted, 2–8°C, dark7–14 daysMinor degradation
Reconstituted, 25°C24–48 hUse promptly
Light exposure (ICH Q1B)1.2 M lux·hGenerally light-stable
Freeze–thaw (−20°C ⇄ 25°C)3 cyclesAcceptable — aliquot to avoid repeats
  • Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
  • Minimise freeze-thaw cycles; aliquot material used across many sessions.
  • Key factor: A single methionine is oxidation-sensitive; protect from air and light.

Selected References

  • Semax (ACTH(4–10) analogue) neuroprotection and BDNF/NGF induction literature.
  • Reviews of regulatory peptides derived from ACTH fragments.

Quality & Supply

  • HPLC ≥ 98% purity with a Certificate of Analysis per batch
  • Identity confirmed by LC-MS
  • Research samples through to bulk, with worldwide delivery
  • Custom quantities and packaging on request

Need Semax — sample or bulk?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote